Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 15/20 | 0.47 |
| ▸ | PDE4A | P27815 | 8/20 | 0.44 |
| ▸ | PDE4C | Q08493 | 4/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.44 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cyclopropanecarboxylic Acid Amide SCHEMBL873615 | 0.97 | PDE4B (0.48) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL873742 | 0.95 | PDE4B (0.48) | PDE4BPDE4APDE4CPDE4D | |
| Cyclopropane Carboxylic Acid SCHEMBL874103 | 0.92 | PDE4B (0.51) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL681826 | 0.92 | PDE4A (0.49) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL2085994 | 0.92 | PDE4A (0.49) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL682038 | 0.85 | PDE4B (0.48) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL2140386 | 0.85 | PDE4B (0.48) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL682651 | 0.85 | PDE4B (0.50) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL2141419 | 0.85 | PDE4B (0.50) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL873257 | 0.84 | PDE4B (0.51) | PDE4BPDE4APDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2643000-A2 | THERAPEUTIC PIPERAZINES | Dart Neuroscience (Cayman) Ltd (KY) | 2013-10-02 | — | — | EP | disclosed |
| WO-2012040258-A2 | THERAPEUTIC PIPERAZINES | HELICON THERAPEUTICS, INC. (US) | 2012-03-29 | — | — | WO | disclosed |